Role Of Phosphorus And FGF 23 In Patients With Dent Disease

Overview

Información sobre este estudio

Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

Patients will be recruited from those in the RKSC Dent Registry

  • Diagnostic criteria for Dent disease include:
    • LMWP (at least 5 times above the upper limit of normal) and at least 1 of the following criteria:
      • Hypercalciuria;
      • Kidney stones;
      • Nephrocalcinosis;
      • Hypophosphatemia;
      • Renal phosphate leak;
      • Aminoaciduria;
      • Glucosuria without diabetes mellitus;
      • Hematuria;
      • Renal insufficiency;
      • Family history with x-linked inheritance; or
    • 1 of the above criteria (1-9) and confirmed genetic mutation of CLCN5 or OCRL1.
  • Idiopathic calcium nephrolithiasis with renal phosphate leak.
  • Male patients > 18 years old.
  • History of symptomatic calcium oxalate or calcium phosphate stone, hypercalciuria (>250 mg/24 hrs), renal phosphate leak (TMP/GFR < 2.07 mg/dl).
  • Idiopathic calcium nephrolithiasis without renal phosphate leak.
  • Male patients > 18 years old.
  • History of symptomatic calcium oxalate or calcium phosphate stone, hypercalciuria (>250 mg/24 hrs), renal phosphate leak (TMP/GFR < 2.07 mg/dl).

Exclusion Criteria:

  • Exclusion for Dent disease include:
    • primary or secondary hyperparathyroidism;
    • hyperthyroidism;
    • chronic diarrhea states;
    • intake of thiazide diuretics;
    • glucocorticoids; or
    • estrogens within one month of the study.
  • Exclusion criteria for calcium stone formers include:
    • primary or secondary hyperparathyroidism;
    • hyperthyroidism;
    • estimated GFR < 40 ml/mn/1.73m^2;
    • chronic diarrhea states;
    • intake of thiazide diuretics;
    • glucocorticoids; or
    • estrogens within one month of the study.
  • Exclusion criteria include history of symptomatic or asymptomatic kidney stone disease; primary or secondary hyperparathyroidism; estimated GFR <40 ml/min/1.73m2, chronic diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens within one month of the study.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

John Lieske, M.D.

Cerrado para la inscripción

Contact information:

Julie Olson R.N., CCRP

(507)538-5995

Olson.Julie@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20118024

Mayo Clinic Footer